PRODUCT

AOD-9604 ( 10mg vial )

No short description available.

Quickstart Highlights

AOD-9604 dosage protocols utilize this synthetic 16-amino-acid fragment (Tyr-hGH 177–191) to support lipolysis (fat breakdown) and inhibit lipogenesis (fat storage) without increasing IGF-1 levels or causing insulin resistance. Clinical trials have shown that AOD-9604 has a placebo-like safety profile in adults with obesity, making it a well-tolerated option for metabolic support. This educational protocol outlines a once-daily subcutaneous injection approach using a practical dilution for accurate insulin syringe measurements.

Reconstitution: Add 3.0 mL of bacteriostatic water to achieve an approximate concentration of 1.667 mg/mL (1667 mcg/mL).
Typical daily range: 300–500 mcg once daily (with gradual dose titration).
Easy measurement: At 1.667 mg/mL, 1 unit = 0.01 mL ≈ 16.67 mcg on a U-100 insulin syringe.
Storage: Lyophilized: store frozen at −20 °C (−4 °F). Reconstituted: refrigerate at 2–8 °C (35.6–46.4 °F). Avoid repeated freeze–thaw cycles.

Reconstitution

Draw 3.0 mL of bacteriostatic water using a sterile syringe.
Inject the diluent slowly down the inside wall of the vial to avoid foaming.
Gently swirl or roll the vial until fully dissolved (do not shake).
Label the vial and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Protocol Overview

Goal:Support fat mass reduction and enhance fat oxidation over time.
Schedule:Daily subcutaneous injections for 8–12 weeks (extend up to 16 weeks if desired).
Dose Range:300–500 mcg daily with gradual titration.
Reconstitution:3.0 mL per 5 mg vial (≈ 1.667 mg/mL) for accurate unit measurements.
Storage:store frozen. Reconstituted: refrigerate. Avoid repeated freeze–thaw cycles.

Dosage Protocols

Start:300 mcg por dia durante as Semanas 1–4; aumentar para 500 mcg durante as Semanas 5–12, conforme a tolerância.
Target:Atingir 500 mcg por dia a partir da Semana 5 e manter essa dose até o final do ciclo.
Frequency:Uma vez ao dia (injeção subcutânea).
Cycle Length:8–12 semanas, com opção de estender até 16 semanas.
Timing:É comum administrar pela manhã em jejum; faça a rotação dos locais de aplicação.

Storage Instructions

Lyophilized:Store at −20 °C (−4 °F) in a dry, dark place. Stable for 1 year or longer.
Reconstituted:Refrigerate at 2–8 °C (35.6–46.4 °F). Use within 3–4 weeks and avoid freeze–thaw cycles.

Important Notes

Practical considerations for consistency and safety.

Use new sterile insulin syringes (U-100, 29–31 gauge) for each administration and dispose of them in a sharps container.
Rotate injection sites (abdomen, thighs, and upper arms) to reduce local irritation and prevent lipohypertrophy.
Inject slowly and wait a few seconds before withdrawing the needle.
Each 5 mg vial provides approximately 10 days of dosing at 500 mcg/day or 16–17 days at 300 mcg/day.

How It Works

AOD-9604 is a modified C-terminal fragment of human growth hormone (hGH) that retains the lipolytic (fat-reducing) activity without the growth-promoting effects. It acts on adipose tissue by stimulating the breakdown of stored fat while reducing the storage of new fat (re-esterification) within adipocytes. At the molecular level, chronic administration of AOD-9604 increases the expression of β3-adrenergic receptors in adipose tissue, helping reverse the obesity-related suppression of these fat-burning receptors. Unlike full-length hGH, AOD-9604 does not significantly increase IGF-1 levels or impair glucose tolerance, demonstrating a placebo-like tolerability profile in clinical studies.

Lifestyle Factors

Pair with a hypocaloric, high-protein diet tailored to individual energy needs. AOD-9604 should be viewed as a supportive aid for fat loss rather than a stand-alone solution.
Combine resistance training with aerobic exercise to reinforce metabolic adaptations.
Prioritize quality sleep and stress management to support recovery and long-term adherence.

Injection Technique

Clean the vial stopper and the skin with alcohol, and allow both to dry completely before administration.
Pinch a skinfold and insert the needle at 90° (or 45° if there is very little subcutaneous tissue).
Do not aspirate during subcutaneous injections; inject slowly and steadily.
Rotate injection sites systematically (abdomen at least 2 inches from the navel, thighs, and upper arms) to help prevent lipohypertrophy.

AOD-9604 ( 10mg vial )

Resources

Categories

Company